Scarica l'app Stockscreener
76.55
0.78%
-0.60
Pre-mercato:
77.55
1.00
+1.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Why (ARWR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
WEALTH EFFECTS LLC's Arrowhead Pharmaceuticals Inc(ARWR) Holding History - GuruFocus
Arrowhead Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Arrowhead Pharmaceuticals lines up SHASTA readout as REDEMPLO launch gains traction - MSN
Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi - Barchart.com
Arrowhead Pharmaceuticals, Inc. Trade Ideas — XETR:HDP1 - TradingView
Net income of Arrowhead Pharmaceuticals, Inc. – XETR:HDP1 - TradingView
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction - Yahoo Finance
Q3 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Competitors 2026 - GuruFocus
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript - GuruFocus
Arrowhead Pharmaceuticals Inc Stock Baskets | BSP:A2RR34 - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Stock News, Headlines & Updates - GuruFocus
Arrowhead Pharmaceuticals Inc Stock Warning Signs - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Stock Price & 30 Year Financial Data - GuruFocus
Arrowhead Pharmaceuticals Inc (BSP:A2RR34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Arrowhead Pharmaceuticals Inc Stock Operating Data - GuruFocus
Homozygous Familial Hypercholesterolemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics - Barchart
Understanding Momentum Shifts in (ARWR) - Stock Traders Daily
Arrowhead Pharmaceuticals Prepares for Key Healthcare Conferences - GuruFocus
Arrowhead Pharmaceuticals Drops 7.0% Amid Sector-Wide Selling - AlphaStreet
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events - BioSpace
Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum - MSN
ViaSat, Arrowhead Pharmaceuticals, and SiTime Lead Stocks with High Returns - Markets Mojo
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results - Sahm
Arrowhead Pharmaceuticals (ARWR) Reveals Promising Interim Trial Results - GuruFocus
Arrowhead presents trial data for obesity treatment candidate - Investing.com UK
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 - Arrowhead Pharmaceuticals, Inc.
Arrowhead presents trial data for obesity treatment candidate By Investing.com - Investing.com Canada
Arrowhead presents new positive clinical data on plozasiran - The Pharma Letter
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus - Yahoo Finance
Arrowhead Pharmaceuticals (ARWR) Reports Clinical Findings for P - GuruFocus
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress - BioSpace
Arrowhead presents plozasiran data on renal, hepatic impairment - Investing.com UK
Arrowhead presents plozasiran data on renal, hepatic impairment By Investing.com - Investing.com Nigeria
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - Insider Monkey
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
ARROWHEAD PHARMACEUTICALS IN (ARWR) Technical Analysis - ChartMill
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next - TipRanks
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - Barchart.com
Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Director Daniel Apel to offer 100,000 ARWR common shares (NASDAQ: ARWR) - Stock Titan
Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR) - Stock Titan
James Hamilton to sell 10,000 shares (ARWR) after prior 10,000-share sale - Stock Titan
Arrowhead Pharmaceuticals eyes $4B Redemplo opportunity as RNAi pipeline readouts near - MSN
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options - Sahm
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):